Arrowhead Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HDP1.F | IONS | ALNY | 4591.T | 688382.SS | ADRX | |
|---|---|---|---|---|---|---|
| Market cap | 7.71B | 6.67B | 21.57B | 3.39B | 8.38B | 1.66B |
| P/E (TTM) | — | — | 8.1 | — | — | — |
| Forward P/E | -113.7 | -35.0 | 14.4 | -1.1 | -43.8 | -9.9 |
| Price/book | 18.6 | 15.1 | 6.0 | 1.2 | 6.6 | -0.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +51.36% | −45.82% | −63.21% | −29.21% | −48.70% | −22.69% |
| Today | −0.15% | −0.67% | +0.74% | −4.76% | +4.33% | −7.02% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All HDP1.F news ›Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November…
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
– Detailed Results from the Phase 1/2a Study of ARO-DIMER-PA, the First Dual-Functional Investigational RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia, Will Be Presented at Late-breaking Featured Science Session.05 on Saturday,…
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and CRISPR Therapeutics (NASDAQ:CRSP) Financial Review
Posted by Sarita Garza on Oct 26th, 2026 CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both mid-cap healthcare companies, but which is the superior business? We will…
UBS Group Upgrades Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “Strong-Buy”
Posted by Kim Johansen on Oct 17th, 2026 Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) was upgraded by investment analysts at UBS Group to a “strong-buy” rating in a report issued on Wednesday, Zacks reports. View Our Latest…
Arrowhead Pharmaceuticals (NASDAQ:ARWR) versus Sera Prognostics (NASDAQ:SERA) Head to Head Review
Posted by Danessa Lincoln on Oct 18th, 2026 Sera Prognostics (NASDAQ:SERA – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the better business? We will contrast…
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Posted by Defense World Staff on Oct 17th, 2026 DBV Technologies (NASDAQ:DBVT – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast…
Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform
(NASDAQ:ARWR) Seeking Alpha - Arrowhead Pharmaceuticals, Inc. exceeded expectations with ARO-MAPT phase 1 results, achieving up to 85% CSF tau reduction and validating its subcutaneous CNS siRNA platform. - ARWR plans to expand its CN
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline Transcript
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses ARO-MAPT Interim Results and TRiM CNS Delivery Platform in Investigational CNS Pipeline October 14, 2026 2:30 PM EDT Vincent Anzalone - Head of Investor Relations & VPDr. Christopher…
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
BioSpace Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Arrowhead Pharmaceuticals reports strong ARO-MAPT phase 1 results, plans multiple CNS trials by 2027
Arrowhead Pharmaceuticals exceeded expectations with its ARO-MAPT phase 1 trial, achieving up to 85% reduction in CSF tau protein, validating its CNS siRNA platform. The company plans to expand its central nervous system (CNS) pipeline by…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- seekingalpha.com3
- themarketsdaily.com3
- stocktitan.net2
- biospace.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 27 articles, not a forecast.